Portal de Periódicos da CAPES

Versican expression is an adverse prognostic factor in MLL-rearranged infant acute lymphoblastic leukaemia

2016; Elsevier BV; Volume: 57; Linguagem: Inglês

10.1016/j.ejca.2015.12.031

1879-0852

Emma M. C. Driessen, Sandra S. Pinhanços, Pauline Schneider, Paola De Lorenzo, Maria Grazia Valsecchi, Rob Pieters, Ronald W. Stam,

Glycosylation and Glycoproteins Research

Acute lymphoblastic leukaemia (ALL) in infants (<1 year) is an aggressive disease, associated with poor clinical outcome [ [1] Biondi A. Cimino G. Pieters R. Pui C.H. Biological and therapeutic aspects of infant leukemia. Blood. 2000; 96: 24-33 PubMed Google Scholar ]. Infant ALL is associated with high incidence of MLL translocations, which are independent predictors of an adverse outcome [ 1 Biondi A. Cimino G. Pieters R. Pui C.H. Biological and therapeutic aspects of infant leukemia. Blood. 2000; 96: 24-33 PubMed Google Scholar , 2 Pieters R. Schrappe M. De Lorenzo P. Hann I. De Rossi G. Felice M. et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet. 2007; 370: 240-250 Abstract Full Text Full Text PDF PubMed Scopus (456) Google Scholar ]. In an attempt to identify genes that improve risk classification for MLL-rearranged infant ALL patients, Kang et al. [ [3] Kang H. Wilson C.S. Harvey R.C. Chen I.M. Murphy M.H. Atlas S.R. et al. Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study. Blood. 2012; 119: 1872-1881 Crossref PubMed Scopus (89) Google Scholar ] build a prediction model for outcome based on gene expression profiling (GEP), based on the expression of 29 Affymetrix microarray probesets, including all probesets (n=5) corresponding to versican (VCAN). The human VCAN gene encoding for the hyaluronan-binding proteoglycan protein versican [ [4] Lebaron R.G. Versican. Perspect Dev Neurobiol. 1996; 3: 261-271 PubMed Google Scholar ]. VCAN plays a role in various cellular processes, including cell adhesion, proliferation, apoptosis, angiogenesis, migration and invasion [ [5] Wight T.N. Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr Opin Cell Biol. 2002; 14: 617-623 Crossref PubMed Scopus (445) Google Scholar ]. Elevated VCAN expression is observed in several types of cancer and is associated with clinical outcome in prostate and breast cancers [ 6 Alizadeh A.A. Bohen S.P. Lossos C. Martinez-Climent J.A. Ramos J.C. Cubedo-Gil E. et al. Expression profiles of adult T-cell leukemia-lymphoma and associations with clinical responses to zidovudine and interferon alpha. Leuk Lymphoma. 2010; 51: 1200-1216 Crossref PubMed Scopus (17) Google Scholar , 7 Ricciardelli C. Brooks J.H. Suwiwat S. Sakko A.J. Mayne K. Raymond W.A. et al. Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with node-negative primary breast cancer. Clin Cancer Res. 2002; 8: 1054-1060 PubMed Google Scholar , 8 Ricciardelli C. Mayne K. Sykes P.J. Raymond W.A. McCaul K. Marshall V.R. et al. Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer. Clin Cancer Res. 1998; 4: 963-971 PubMed Google Scholar ]. We studied the prognostic value of VCAN expression alone in cohort infant ALL patients.